PMID- 34727330
OWN - NLM
STAT- MEDLINE
DCOM- 20220405
LR  - 20220405
IS  - 1867-108X (Electronic)
IS  - 1867-1071 (Linking)
VI  - 40
IP  - 4
DP  - 2022 Apr
TI  - Hepatic arterial infusion chemotherapy following simultaneous metallic stent 
      placement and iodine-125 seed strands for advanced cholangiocarcinoma causing 
      malignant obstructive jaundice: a propensity score matching study.
PG  - 396-403
LID - 10.1007/s11604-021-01212-7 [doi]
AB  - OBJECTIVE: This study aims to evaluate the effectiveness and safety of hepatic 
      arterial infusion chemotherapy (HAIC) following the simultaneous placement of 
      self-expandable metallic stent (SEMS) and iodine-125 ((125)I) seed strands for 
      the management of advanced cholangiocarcinoma (CCA) patients presenting with 
      malignant obstructive jaundice (MOJ). METHODS: Data from 74 patients with MOJ 
      caused by advanced CCA treated with stent placement with (125)I seed strands with 
      or without HAIC between November 2015 and October 2020 were analysed 
      retrospectively. Eighteen patients received 5 sessions of HAIC after SEMS 
      placement with (125)I seed strands (HAIC group), and 56 patients only underwent 
      SEMS placement with (125)I seed strands and served as controls (control group). 
      HAIC consisted of infusions of gemcitabine (600-1000 mg/m(2) given over 30 min) 
      followed by oxaliplatin (60-100 mg/m(2) given over 2 h), with an interval of 
      4 weeks. Propensity score matching (PSM) analysis was used to adjust for 
      differences in the baseline characteristics of the groups (including age, total 
      bilirubin, and serum alanine aminotransferase level). Overall survival (OS), 
      stent patency, and adverse events were compared between the two groups. RESULTS: 
      OS and stent patency were significantly better in patients in the HAIC group than 
      in those in the control group (median survival time: before PSM, 362 vs. 
      185 days, p = 0.005; after PSM, 357 vs. 183 days, p = 0.012; median duration of 
      stent patency: before PSM, 294 vs. 156 days, p = 0.001; after PSM, 287 vs. 
      183 days, p = 0.039). All adverse reactions were controllable by temporary 
      symptomatic treatment. Serious complications and treatment-related deaths were 
      not observed. CONCLUSION: Our preliminary study showed that HAIC following SEMS 
      placement with (125)I seed strands is effective and safe for the management of 
      advanced CCA patients presenting with MOJ and could improve stent patency and 
      patient survival.
CI  - (c) 2021. Japan Radiological Society.
FAU - Wu, Jun-Zheng
AU  - Wu JZ
AD  - Department of Interventional Radiology, The First Affiliated Hospital of Nanjing 
      Medical University, 300 Guangzhou Road, Gulou District, Nanjing, 210029, China.
FAU - Li, Cong-Lei
AU  - Li CL
AD  - Department of Interventional Radiology, The Fourth People's Hospital of Taizhou, 
      99 Guloubei Road, Hailing District, Taizhou, 225300, China.
FAU - Shi, Hai-Bin
AU  - Shi HB
AD  - Department of Interventional Radiology, The First Affiliated Hospital of Nanjing 
      Medical University, 300 Guangzhou Road, Gulou District, Nanjing, 210029, China.
FAU - Liu, Sheng
AU  - Liu S
AD  - Department of Interventional Radiology, The First Affiliated Hospital of Nanjing 
      Medical University, 300 Guangzhou Road, Gulou District, Nanjing, 210029, China.
FAU - Yang, Wei
AU  - Yang W
AD  - Department of Interventional Radiology, The First Affiliated Hospital of Nanjing 
      Medical University, 300 Guangzhou Road, Gulou District, Nanjing, 210029, China.
FAU - Zhou, Wei-Zhong
AU  - Zhou WZ
AUID- ORCID: 0000-0001-8013-5607
AD  - Department of Interventional Radiology, The First Affiliated Hospital of Nanjing 
      Medical University, 300 Guangzhou Road, Gulou District, Nanjing, 210029, China. 
      xmjbq007@163.com.
LA  - eng
PT  - Journal Article
DEP - 20211102
PL  - Japan
TA  - Jpn J Radiol
JT  - Japanese journal of radiology
JID - 101490689
RN  - 0 (Iodine Radioisotopes)
RN  - GVO776611R (Iodine-125)
SB  - IM
MH  - *Bile Duct Neoplasms/complications/therapy
MH  - Bile Ducts, Intrahepatic
MH  - *Cholangiocarcinoma/complications/therapy
MH  - Humans
MH  - Iodine Radioisotopes
MH  - *Jaundice, Obstructive/etiology/therapy
MH  - Propensity Score
MH  - Retrospective Studies
MH  - *Self Expandable Metallic Stents/adverse effects
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Cholangiocarcinoma
OT  - Hepatic arterial infusion chemotherapy
OT  - Hepatic artery
OT  - Iodine-125 seed strands
EDAT- 2021/11/03 06:00
MHDA- 2022/04/06 06:00
CRDT- 2021/11/02 17:28
PHST- 2021/08/18 00:00 [received]
PHST- 2021/10/21 00:00 [accepted]
PHST- 2021/11/03 06:00 [pubmed]
PHST- 2022/04/06 06:00 [medline]
PHST- 2021/11/02 17:28 [entrez]
AID - 10.1007/s11604-021-01212-7 [pii]
AID - 10.1007/s11604-021-01212-7 [doi]
PST - ppublish
SO  - Jpn J Radiol. 2022 Apr;40(4):396-403. doi: 10.1007/s11604-021-01212-7. Epub 2021 
      Nov 2.